DYNT: AI 评分 39/100 — AI 分析 (4月 2026)

Dynatronics Corporation designs, develops, manufactures, and sells medical devices for physical therapy, rehabilitation, and pain management. The company filed for Chapter 7 liquidation in January 2026.

Key Facts: AI Score: 39/100 Sector: Healthcare

公司概况

概要：

Dynatronics Corporation, operating in the medical device sector, specializes in physical therapy, rehabilitation, and orthopedic products. The company markets its products under various brand names through a network of independent dealers. However, Dynatronics filed for Chapter 7 liquidation in early 2026, introducing substantial uncertainty.

DYNT是做什么的？

Dynatronics Corporation, established in 1979 and headquartered in Eagan, Minnesota, has been a player in the medical device industry, focusing on the design, development, manufacturing, marketing, and sales of products for physical therapy, rehabilitation, orthopedics, pain management, and athletic training. The company's product portfolio includes orthopedic soft bracing products like cervical collars, arm slings, knee supports, and ankle walkers, alongside physical therapy and rehabilitation equipment such as electrotherapy devices, ultrasound machines, and treatment tables. Dynatronics markets its products under well-known brands like Dynatron, Dynatron Solaris, Bird & Cronin, Hausmann, PROTEAM, and Mammoth. These products are distributed through a network of independent dealers, reaching orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, and hospitals across the United States, Asia, Latin America, and the Middle East. However, on January 9, 2026, Dynatronics and its affiliates filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Minnesota, signaling a significant turning point for the company and its stakeholders.

DYNT的投资论点是什么？

Investing in Dynatronics Corporation presents significant risks due to its Chapter 7 liquidation filing in January 2026. The company's negative profit margin of -40.0% and ROE of -127.4% highlight financial instability. While the company has a gross margin of 21.5%, its high debt-to-equity ratio of 225.55 indicates substantial leverage. The company's beta of 0.31 suggests lower volatility compared to the market. Given the liquidation filing, the value of Dynatronics' assets and the potential recovery for investors are highly uncertain. Any investment decision should carefully consider these factors.

DYNT在哪个行业运营？

Dynatronics Corporation operates within the competitive medical device industry, which is characterized by technological innovation, stringent regulatory requirements, and evolving healthcare practices. The industry includes companies that manufacture a wide range of products, from orthopedic implants to diagnostic equipment. Key trends include the increasing demand for minimally invasive procedures, the growing adoption of telehealth, and the rising prevalence of chronic diseases. Dynatronics focuses on the rehabilitation and pain management segments. However, the company's recent Chapter 7 filing places it in a precarious position within this landscape.

Medical Devices

Healthcare

DYNT有哪些增长机遇？

Expansion into Telehealth and Remote Monitoring: Dynatronics could explore opportunities in telehealth and remote patient monitoring solutions, leveraging its existing product lines in rehabilitation and pain management. The global telehealth market is projected to reach $55.6 billion by 2027, growing at a CAGR of 25.8% from 2020 to 2027, according to Allied Market Research. This could involve developing connected devices and platforms that allow patients to receive therapy and monitor their progress remotely. However, given the Chapter 7 filing, this opportunity is unlikely to be pursued.
Development of Advanced Wound Care Products: Dynatronics could invest in the development of advanced wound care products, such as bioactive dressings and negative pressure wound therapy devices. The global advanced wound care market is expected to reach $22.0 billion by 2027, growing at a CAGR of 6.5% from 2020 to 2027, according to a report by MarketsandMarkets. This could involve partnering with research institutions and universities to develop innovative wound care solutions. However, the Chapter 7 filing casts doubt on the company's ability to pursue this avenue.
Penetration of Emerging Markets: Dynatronics could expand its presence in emerging markets, such as China and India, where there is a growing demand for physical therapy and rehabilitation products. The healthcare market in these countries is expanding rapidly due to rising incomes and increasing access to healthcare services. However, the company's Chapter 7 filing makes international expansion highly improbable.
Strategic Partnerships and Acquisitions: Dynatronics could pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. This could involve partnering with complementary companies in the medical device industry or acquiring smaller companies with innovative technologies. However, the Chapter 7 filing significantly limits the company's ability to engage in such activities.
Focus on Sports Medicine and Athletic Training: Dynatronics could focus on the sports medicine and athletic training market, developing specialized products for athletes and sports enthusiasts. The global sports medicine market is expected to reach $8.7 billion by 2025, growing at a CAGR of 7.8% from 2020 to 2025, according to a report by Grand View Research. This could involve partnering with sports teams and athletic organizations to promote its products. However, the Chapter 7 filing makes this strategy difficult to execute.

Negative Profit Margin: Dynatronics has a profit margin of -40.0%, indicating the company is not profitable.
Low Gross Margin: The company's gross margin is 21.5%, which is relatively low for the medical device industry.
High Debt-to-Equity Ratio: Dynatronics has a debt-to-equity ratio of 225.55, signaling high financial leverage.
Negative Return on Equity: The company's ROE is -127.4%, reflecting poor profitability relative to equity.
Chapter 7 Liquidation Filing: Dynatronics filed for Chapter 7 liquidation on January 9, 2026, indicating significant financial distress.

DYNT提供哪些产品和服务？

Designs and develops medical devices for physical therapy and rehabilitation.
Manufactures and markets orthopedic soft bracing products.
Offers therapeutic modality devices, including electrotherapy and ultrasound equipment.
Provides treatment tables, mat platforms, and other related equipment.
Sells products under the Dynatron, Bird & Cronin, and Hausmann brand names.
Distributes products through a network of independent dealers.
Filed for Chapter 7 liquidation in January 2026.

DYNT如何赚钱？

Designs, manufactures, and sells medical devices and related equipment.
Generates revenue through sales to orthopedists, physical therapists, and other healthcare professionals.
Utilizes a network of independent dealers for distribution.
Markets products under multiple brand names.

Orthopedists
Physical therapists
Chiropractors
Athletic trainers
Sports medicine practitioners
Clinics and hospitals

Brand recognition through established brands like Dynatron and Bird & Cronin.
Established distribution network of independent dealers.
Diverse product portfolio in physical therapy and rehabilitation.
Long-standing presence in the medical device industry (founded in 1979).

什么因素可能推动DYNT股价上涨？

Ongoing: Chapter 7 liquidation proceedings may lead to asset sales or restructuring.
Ongoing: Potential for strategic partnerships or acquisitions of Dynatronics' assets by other companies.

DYNT的主要风险是什么？

Ongoing: Chapter 7 liquidation may result in little to no recovery for shareholders.
Potential: Legal and regulatory risks associated with the liquidation process.
Potential: Loss of brand reputation and customer relationships.
Potential: Economic downturns could further impact the company's financial situation.

DYNT的核心优势是什么？

Established brand names (Dynatron, Bird & Cronin, Hausmann).
Diverse product portfolio.
Distribution network of independent dealers.
Long-standing presence in the market.

DYNT的劣势是什么？

Negative profit margin.
High debt-to-equity ratio.
Low gross margin.
Chapter 7 liquidation filing.

DYNT有哪些机遇？

Expansion into telehealth and remote monitoring.
Development of advanced wound care products.
Penetration of emerging markets.
Strategic partnerships and acquisitions.

DYNT面临哪些威胁？

Intense competition in the medical device industry.
Stringent regulatory requirements.
Technological obsolescence.
Economic downturns.
Chapter 7 liquidation proceedings.

Key Metrics

MoonshotScore: 39/100

Company Profile

Headquarters: Eagan, United States
Employees: 88

AI Insight

AI analysis pending for DYNT

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Dynatronics Corporation do?

Dynatronics Corporation designs, develops, manufactures, and sells medical devices and equipment for physical therapy, rehabilitation, orthopedics, pain management, and athletic training. The company offers a range of products, including orthopedic soft bracing products, therapeutic modality devices, and treatment tables. Dynatronics markets its products under brand names such as Dynatron, Bird & Cronin, and Hausmann, distributing them through a network of independent dealers to healthcare professionals and institutions. However, Dynatronics filed for Chapter 7 liquidation in January 2026, indicating significant financial distress and uncertainty about its future operations.

What do analysts say about DYNT stock?

AI analysis is pending for Dynatronics (DYNT). However, given the company's Chapter 7 liquidation filing in January 2026, traditional stock analysis may not be relevant. Investors should focus on the liquidation process and the potential recovery of assets. The company's negative profit margin of -40.0% and high debt-to-equity ratio of 225.55% highlight its financial challenges. Any investment decision should be made with caution and after consulting with a financial advisor.

What are the main risks for DYNT?

The primary risk for Dynatronics (DYNT) is the Chapter 7 liquidation filing, which indicates that the company is unable to pay its debts and is seeking to liquidate its assets. This process may result in little to no recovery for shareholders, as creditors are typically prioritized in bankruptcy proceedings. Other risks include the potential loss of brand reputation, customer relationships, and the impact of economic downturns on the company's financial situation. Investors should carefully consider these risks before making any investment decisions.